DCHA as Postremission Therapy for AML With t(8;21)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-01

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute myelocytic leukemia ( AML) is a highly heterogeneous group of malignant hematopathy. Chromosomal translocation with t (8; 21) (q22; q22) , about 10 \~ 15% incidence in AML and 40% incidence in the AML-M2 type of leukemia, is a karyotype that is considered to have a good prognosis. The National Comprehensive Cancer Network (NCCN) guidelines recommend that high-dose Ara-c regimens may benefit for patients, but with 30 to 40% relapse and serious risks on myelosuppression, infection and bleeding in high-dose Ara-c consolidation chemotherapy and more than 70% recurrence rate with （tyrosine kinase）KIT mutation. So the exploration of a relatively safe and efficient consolidation therapy is one of the difficult problems to be solved in the treatment of mitigatory t (8; 21) AML.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）

NCT01690507

MDS AML

COMPLETED PHASE1/PHASE2

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

NCT01627041

Acute Myeloid Leukemia Adult Acute Basophilic Leukemia Adult Acute Monoblastic Leukemia +7 more

ACTIVE_NOT_RECRUITING PHASE2

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

NCT03417427

Leukemia, Myeloid

UNKNOWN PHASE2

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

NCT01729845

Previously Treated Myelodysplastic Syndrome Recurrent Adult Acute Myeloid Leukemia

COMPLETED PHASE1/PHASE2

10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1

NCT02252107

Acute Myeloid Leukemia (AML)

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Treatment regimen

HA:

homoharringtonine 2mg IV d1-5 cytarabine( Ara-C) 1500mg/m2(\<60 year old) ; 1000mg/m2(\>60 year old) IV q12h

DCHA:

Decitabine 20mg/m2 d8-12 Chidamide 30mg twice/week P.O. for two weeks per cycle (four doses totally) cytarabine( Ara-C) 1500mg/m2(\<60 year old) ; 1000mg/m2(\>60 year old) IV q12h d1,3,5 homoharringtonine 2mg IV d10-14

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chemotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

t(8;21)AML

chemotherapy 5-Aza-2'-deoxycytidine IV 20mg/m2 d8-12 homoharringtonine IV 2mg d1-5 chidamide P.O. 30mg twice/W cytarabine IV 1000mg/m2(\<60 year old) 500mg/m2(\>60 year old) IV q12h d1,3,5

Group Type EXPERIMENTAL

Chemotherapy

Intervention Type DRUG

chidamide, decitabine, homoharringtonine, cytarabine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chemotherapy

chidamide, decitabine, homoharringtonine, cytarabine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DCHA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Written informed consent provided.

* The patients were diagnosed AML-M2 with t(8;21) (q22;q22) chromosomal changes and positive acute myeloid leukemia(AML1)-eight twenty one(ETO) fusion gene according to the 2008 World Health Organization (WHO) diagnostic criteria for malignant myeloid diseases.
* Males or females aged ≥18 years, \< 65 years.
* Eastern Cooperative Oncology Group（ECOG） performance status 0-3.
* Life expectancy ≥3 months.
* The morphology was Complete remission (CR) or Cri after 2 cycles of anthracycline induced chemotherapy.
* No serious disease with heart, lung, liver and kidney.
* The ability to understand and be willing to sign the Informed Consent Form of the experiment.
* Patient who can start the investigational therapy within 3-6 weeks after the complete resection
* Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN in subjects without liver metastases; ≤ 5 x ULN in subjects with liver metastases.
* Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml/min.
* Female subjects should not be pregnant or breast-feeding.

Exclusion Criteria

* Known allergic to prior treatment with drugs contained by the trial programme or with a chemical structure similar medicine.
* Pregnancy, breast-feeding women and childbearing age patients who do not want to take contraceptive measures.
* Active serious infection.
* Patients with extramedullary lesions.
* Patients who use drugs or drink alcohol for a long time to influence the evaluation of results.
* Patients with mental illness or other conditions are unable to obtain knowledge and consent, and can not cooperate with the requirements of the completion of the test treatment and examination steps.
* Patients with a history of the clinical significance of Q and T interval（QTc） prolongation (male \> 450ms, female \>470ms), ventricular tachycardia (VT), atrial fibrillation (AF), degree of heart block, muscle infarction (MI) within 1 years, congestive heart failure (CHF), with symptoms and drug therapy in patients with coronary heart disease.
* Patients with abnormal liver function (total bilirubin \> 1.5 x ULN, ALT/AST \> 2.5 x ULN, or liver invasion ALT/AST \> 5x ULN ), renal function abnormality (serum creatinine \> 1.5 x ULN).
* The researchers decided that patient was not appropriate to take part in the experiment.

Minimum Eligible Age

14 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No